Stay updated with breaking news from Tokyo Based Eisai. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eisai London, April 2nd, 2024 - CNX Therapeutics Limited (“CNX Therapeutics”), a speciality pharmaceutical company with a portfolio of medicines for the treatment of central nervous system (CNS) disorders and hospital emergencies in over 40 countries worldwide, is pleased to announce that it has suc...
Adjusted earnings for the year will be $14.50 to $15.00 a share, down from the earlier range of $15 to $16, Biogen said in a statement Wednesday.
Cambridge-based Biogen is cutting costs while broadening its focus to replace declining revenue from multiple sclerosis therapies, which made up more than half the drugmaker’s 2022 sales.
An experimental version of Eisai Co.’s Alzheimer’s drug that might be given in patients’ homes exceeded the power of Leqembi, its approved infused formulation, in an early study that could
By Colin Kellaher A pair of late-stage studies of a cancer-drug combination from Merck & Co. and Eisai missed their main goals in patients with certain types of metastatic non-small cell lung...